FDA Clearance Tracker · P240035-S002
ETHIZIA Hemostatic Patch
Last checked: Nov 20, 2026Latest source record: Jun 25, 2026 (this decision)Source: openFDAMethods & limitations
Decided
Jun 25, 2026
Approved
Time to decision
178 days
Received Dec 29, 2025. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Panel Track
Device class
Class III
The decision
- FDA number
- P240035-S002
- Device name
- ETHIZIA Hemostatic Patch
- Applicant
- ETHICON, Inc.
- Applicant location
- Raritan, NJ
- Received
- Dec 29, 2025
- Decided
- Jun 25, 2026
- Decision
- Approved
- Supplement type
- Panel Track
- Reason for supplement
- Labeling Change - Indications/instructions/shelf life/tradename
- Original approval
- P240035
Device type
- Device class
- Class III
- Regulation
- 21 CFR 878.4490
- Specialty
- General & Plastic SurgeryWound Care
FDA's approval statement
As written in FDA's record.
approval for the ETHIZIA Hemostatic Patch for expanding the indications to include minimally invasive surgical procedures on the liver.
Source documents
Other decisions for ETHICON, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K253394 · Decided Jun 25, 2026 · 268 days after receipt
Device type: Suture, Absorbable, Synthetic, Polyglycolic Acid (GAM) · General & Plastic Surgery
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.